Nils-Olof Bengtsson

Publications

Author

Title

Year sorteringsordning

Fulltext

Rosell, Johan
Nordenskjold, Bo
Bengtsson, Nils-Olof; et al.

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
Acta Oncologica, 56(4): 614-617

2017

-

Rosell, Johan
Nordenskjold, Bo
Bengtsson, Nils-Olof; et al.

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
Breast Cancer Research and Treatment, 138(2): 467-473

2013

-

McGale, Paul
Darby, Sarah C.
Hall, Per; et al.

Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden
Radiotherapy and Oncology, 100(2): 167-175

2011

-

Chadda, S.
Larkin, M.
Jones, C.; et al.

The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a european perspective
Value in Health, 14(3): A173-A173

2011

-

Edlund, Per
Ahlgren, Johan
Bjerre, Karsten; et al.

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
Acta Oncologica, 50(3): 329-337

2011

-

Rosell, Johan
Nordenskjöld, B
Bengtsson, Nils-Olof; et al.

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
British Journal of Cancer, 104(6): 899-902

2011

-

Margolin, Sara
Bengtsson, Nils-Olof
Carlsson, Lena; et al.

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Acta Oncologica, 50(1): 35-41

2011

-

Sjöström-Mattson, Johanna
Von Boguslawski, Kristina
Bengtsson, Nils-Olof; et al.

The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
Acta oncologica (Stockholm, Sweden), 48(8): 1137-1143

2009

-

Villman, Kenneth
Sjöström, Johanna
Heikkilä, Reino; et al.

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
Acta Oncol, 45(5): 590-596

2006

-

Ejlertsen, Bent
Mouridsen, Henning T
Jensen, Maj-Britt; et al.

Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer
J Clin Oncol, 24(31): 4956-4962

2006

-


Page Editor: Maria Wing

Print page